CoChat
Sign Up
Cited by 51Aluminum toxicity and tolerance in plants and animalsFibromyalgia and Chronic Fatigue Syndrome ResearchLong-Term Effects of COVID-19

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Clinical Features in Patients with Long-Lasting Macrophagic Myofasciitis

Open access
Rigolet, Muriel, Aouizerate, Jessie, Couette, Maryline, Ragunathan-Thangarajah, Nilusha, Aoun-Sebaiti, Mehdi, Gherardi, Romain Kroum, Cadusseau, Josette, Authier, François Jérôme·2014·Frontiers in Neurology
DOI 10.3389/fneur.2014.00230PMC PMC4246686
Open this paper in CoChat — free accountOpen PDF

Abstract

Macrophagic myofasciitis (MMF) is an emerging condition characterized by specific muscle lesions assessing abnormal long-term persistence of aluminum hydroxide within macrophages at the site of previous immunization. Affected patients usually are middle-aged adults, mainly presenting with diffuse arthromyalgias, chronic fatigue, and marked cognitive deficits, not related to pain, fatigue, or depression. Clinical features usually correspond to that observed in chronic fatigue syndrome/myalgic encephalomyelitis. Representative features of MMF-associated cognitive dysfunction include dysexecutive syndrome, visual memory impairment, and left ear extinction at dichotic listening test. Most patients fulfill criteria for non-amnestic/dysexecutive mild cognitive impairment, even if some cognitive deficits appear unusually severe. Cognitive dysfunction seems stable over time despite marked fluctuations. Evoked potentials may show abnormalities in keeping with central nervous system involvement, with a neurophysiological pattern suggestive of demyelination. Brain perfusion SPECT shows a pattern of diffuse cortical and subcortical abnormalities, with hypoperfusions correlating with cognitive deficiencies. The combination of musculoskeletal pain, chronic fatigue, and cognitive disturbance generates chronic disability with possible social exclusion. Classical therapeutic approaches are usually unsatisfactory making patient care difficult.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2014.00230

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 41

  1. Gherardi, 1998, Macrophagic myofasciitis: an emerging entity. Groupe d’Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l’Association Française contre les Myopathies (AFM), Lancet, 352, 347, 10.1016/S0140-6736(98)02326-5 · DOI
  2. Gherardi, 2001, Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle, Brain, 124, 1821, 10.1093/brain/124.9.1821 · DOI
  3. Authier, 2006, AlOH3-adjuvanted vaccine-induced macrophagic myofasciitis in rats is influenced by the genetic background, Neuromuscul Disord, 16, 347, 10.1016/j.nmd.2006.02.004 · DOI
  4. Gherardi, 2012, Macrophagic myofasciitis: characterization and pathophysiology, Lupus, 21, 184, 10.1177/0961203311429557 · DOI · Paper page
  5. Couette, 2009, Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction, J Inorg Biochem, 103, 1571, 10.1016/j.jinorgbio.2009.08.005 · DOI
  6. Passeri, 2011, Long-term follow-up of cognitive dysfunction in patients with aluminum hydroxide-induced macrophagic myofasciitis (MMF), J Inorg Biochem, 105, 1457, 10.1016/j.jinorgbio.2011.08.006 · DOI
  7. Ragunathan-Thangarajah, 2013, Distinctive clinical features in arthro-myalgic patients with and without aluminum hydroxyde-induced macrophagic myofasciitis: an exploratory study, J Inorg Biochem, 128, 262, 10.1016/j.jinorgbio.2013.07.020 · DOI
  8. Kissel, 2007, Muscle biopsy in patients with myalgia: Still a painful decision, Neurology, 68, 170, 10.1212/01.wnl.0000254503.91471.f5 · DOI
  9. WHO Vaccine Safety Advisory Committee, 1999, Macrophagic myofasciitis and aluminum-containing vaccines, Wkly Epidemiol Rec, 74, 337
  10. Verdier, 2005, Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the cynomolgus monkey, Vaccine, 23, 1359, 10.1016/j.vaccine.2004.09.012 · DOI
  11. Khan, 2013, Slow CCL2-dependent translocation of biopersistent particles from muscle to brain, BMC Med, 11, 99, 10.1186/1741-7015-11-99 · DOI
  12. Gherardi, 2003, Aluminum inclusion macrophagic myofasciitis: a recently identified condition, Immunol Allergy Clin North Am, 23, 699, 10.1016/S0889-8561(03)00095-X · DOI
  13. Caulfield, 2007, Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice, Hum Vaccin, 3, 139, 10.4161/hv.3.4.4309 · DOI
  14. Siegrist, 2003, Vaccine adjuvants and macrophagic myofasciitis, Bull Acad Natl Med., 187, 1511
  15. Papo, 2003, Macrophagic myofasciitis: focal or systemic?, Joint Bone Spine, 70, 242, 10.1016/S1297-319X(03)00093-9 · DOI
  16. McKee, 2010, Immune mechanisms of protection: can adjuvants rise to the challenge?, BMC Biol, 8, 37, 10.1186/1741-7007-8-37 · DOI
  17. Flarend, 1997, In vivo absorption of aluminium-containing vaccine adjuvants using 26 Al, Vaccine, 15, 1314, 10.1016/S0264-410X(97)00041-8 · DOI
  18. InVS (Institut de Veille Sanitaire), 2001, [Exploratory Report on Macrophagic Myofasciitis]
  19. AFSSAPS (Agence Française de Sécurité sanitaire des Produits de Santé), 2003, [Exploratory Epidemiological Survey of Macrophagic Myofasciitis]
  20. Wolfe, 1990, The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee, Arthritis Rheum, 33, 160, 10.1002/art.1780330203 · DOI · Paper page
  21. Chérin, 2000, Gallium-67 scintigraphy in macrophagic myofasciitis, Arthritis Rheum, 43, 1520, 10.1002/1529-0131(200007)43:71520::AID-ANR163.0.CO;2-Q · DOI
  22. Authier, 2001, Central nervous system disease in patients with macrophagic myofasciitis, Brain, 124, 974, 10.1093/brain/124.5.974 · DOI
  23. Guis, 2002, Identical twins with macrophagic myofasciitis: genetic susceptibility and triggering by aluminic vaccine adjuvants?, Arthritis Rheum, 47, 543, 10.1002/art.10666 · DOI
  24. Guis, 2002, HLA-DRB1*01 and macrophagic myofasciitis, Arthritis Rheum, 46, 2535, 10.1002/art.10465 · DOI
  25. Authier, 2003, Chronic fatigue syndrome in patients with macrophagic myofasciitis, Arthritis Rheum, 48, 569, 10.1002/art.10740 · DOI
  26. Guis, 2004, MRI and 31PMR spectroscopy investigations of muscle function disclose no abnormality in macrophagic myofasciitis, J Rheumatol., 31, 2313
  27. Santiago, 2014, Macrophagic myofasciitis and vaccination: Consequence or coincidence?, Rheumatol Int, 10.1007/s00296-914-3065-4 · DOI
  28. McMahon, 1992, Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons, Am J Med., 92, 254, 10.1016/0002-9343(92)90073-K · DOI
  29. Exley, 2009, A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome, Med Hypotheses, 72, 135, 10.1016/j.mehy.2008.09.040 · DOI
  30. Chérin, 2001, Macrophagic myofasciitis associated with inclusion body myositis: a report of three cases, Neuromuscul Disord, 11, 452, 10.1016/S0960-8966(01)00194-8 · DOI
  31. Lazaro, 2005, [Coexistence of dermatomyositis and macrophagic myofasciitis], Presse Med, 34, 438, 10.1016/S0755-4982(05)83938-7 · DOI
  32. Israeli, 2011, Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease, Clin Rev Allergy Immunol, 41, 163, 10.1007/s12016-010-8212-4 · DOI
  33. Landay, 1991, Chronic fatigue syndrome: clinical condition associated with immune activation, Lancet, 338, 707, 10.1016/0140-6736(91)91440-6 · DOI
  34. Agmon-Levi, 2008, Chronic fatigue syndrome with autoantibodies – the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant, Autoimmun Rev, 8, 52, 10.1016/j.autrev.2008.07.026 · DOI
  35. Aggarwal, 1995, Common and uncommon features of cytokines and cytokine receptors: an overview, 3
  36. Dinarello, 1996, Biologic basis for interleukin-1 in disease, Blood, 87, 2095, 10.1182/blood.V87.6.2095.bloodjournal8762095 · DOI · Paper page
  37. Komaroff, 1998, Chronic fatigue syndrome: an update, Annu Rev Med, 49, 1, 10.1146/annurev.med.49.1.1 · DOI
  38. Cadusseau, 2014, Selective elevation of circulating CCL2/MCP1 levels in patients with longstanding post-vaccinal macrophagic myofasciitis and ASIA, Curr Med Chem, 21, 511, 10.2174/09298673113206660287 · DOI
  39. Amoura, 2000, Familial macrophagic myofasciitis, Ann Rheum Dis, 59, 927, 10.1136/ard.59.11.926b · DOI
  40. Nevo, 2004, Childhood macrophagic myofasciitis-consanguinity and clinicopathological features, Neuromuscul Disord, 14, 246, 10.1016/j.nmd.2003.12.005 · DOI
  41. Shoenfeld, 2011, ‘ASIA’ – autoimmune/inflammatory syndrome induced by adjuvants, J Autoimmun, 36, 4, 10.1016/j.jaut.2010.07.003 · DOI

Cited by

Sorted by citations

  • Aluminium toxicosis: a review of toxic actions and effects

    Igbokwe, I. O., Igwenagu, E., & Igbokwe, N. A. (2019) · Interdisciplinary Toxicology · doi:10.2478/intox-2019-0007 · Cited by 395

    “Musculoskeletal effects The major myopathy induced by Al exposure is macrophagic myofasciitis (aluminic granuloma) associated with chronic arthromyalgia or myalgia and chronic fatigue syndrome (Exley et al., 2009; Gherardi and Authier, 2012; Rigolet et al., 2014; Gherardi et al., 2016; Miller, 2016).”
    Background

See all 51

Metadata

Authors
Rigolet, M., Aouizerate, J., Couette, M., Ragunathan-Thangarajah, N., Aoun-Sebaiti, M., Gherardi, R. K., Cadusseau, J., & Authier, F. J.
Affiliations
  • Inserm (FR)
  • Centre Hospitalier Universitaire Henri-Mondor (FR)
  • Université Paris-Est Créteil (FR)
ORCID
Venue
Frontiers in Neurology
Publisher
Frontiers Media SA
Published
2014-11-28
Volume
5
Pages
230-230
ISSN
1664-2295 (ISSN-L)
DOI
10.3389/fneur.2014.00230
PMC
PMC4246686
OpenAlex
W2114230104
Cited by
51
References
1
Citations by year
2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 10 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 6 · 2015: 7
FWCI
0.76
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Aluminum toxicity and tolerance in plants and animals
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
  • Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
Keywords
macrophagic myofasciitis, aluminum hydroxide, chronic fatigue syndrome, cognitive impairment, dysexecutive syndrome, mild cognitive impairment, arthromyalgia, chronic fatigue, brain perfusion SPECT, evoked potentials, demyelination, social exclusion, chronic disability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review